Fig. 6.

Oncogenic mutants of SHP2 negatively impact allosteric inhibition in SHP2-deficient U2OS cells. a Western blot quantification of SHP2 expression levels in wild-type U2OS cells (U2OS) and in SHP2-deficient U2OS cells (PTPN11-null) in the presence and absence of expression of SHP2 oncogenic variants. b Western blot analysis showing relative pErk levels in wild-type, SHP2-deficient, and SHP2-rescued U2OS cells. c Western blot determination of pErk levels in SHP2-deficient U2OS cells, in the presence and absence of the SHP2 allosteric inhibitor SHP099. d Quantification of pErk levels in SHP2-deficient U2OS cells expressing SHP2^WT and oncogenic mutants upon titration of SHP099. Data points are presented as mean ± standard error of the mean